Tristel PLC

LSE TSTL.L

Tristel PLC Return on Capital Employed (ROCE) for the year ending June 30, 2024: 19.46%

Tristel PLC Return on Capital Employed (ROCE) is 19.46% for the year ending June 30, 2024, a 30.94% change year over year. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.

Tristel PLC Return on Capital Employed (ROCE) for the year ending June 30, 2023 was 14.86%, a 194.70% change year over year.
Tristel PLC Return on Capital Employed (ROCE) for the year ending June 30, 2022 was 5.04%, a -54.12% change year over year.
Tristel PLC Return on Capital Employed (ROCE) for the year ending June 30, 2021 was 10.99%, a -44.67% change year over year.
Tristel PLC Return on Capital Employed (ROCE) for the year ending June 30, 2020 was 19.86%, a 1.90% change year over year.

Key data

Date	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio	Return on Common Equity

LSE: TSTL.L

Tristel PLC

CEO	Mr. Matthew G. Sassone
IPO Date	June 1, 2005
Location	United Kingdom
Headquarters	Lynx Business Park
Employees	250
Sector	Health Care
Industries Pharmaceuticals

Description

Tristel plc develops, manufactures, and sells infection prevention products in the United Kingdom and internationally. The company operates through three segments: Hospital Medical Device Decontamination, Hospital Environmental Surface Disinfection, and Other. It offers medical instrument disinfection products, including airway management, cardiology, ear, nose and throat, endoscopy, gastrointestinal physiology, laboratory, ophthalmology, phlebotomy, reproductive health/IVF, surface, ultrasound, urology, women's health, and other products under the Tristel brand. Tristel plc was founded in 1993 and is headquartered in Snailwell, the United Kingdom.

Key trends

Past 5 years